Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study.*
Christopher J. Hoimes, DO
Note that the poster includes new data and is entitled “Exploratory Subgroup Outcomes in the Phase 3 KEYNOTE-B15 Study of Neoadjuvant-Adjuvant Enfortumab Vedotin Plus Pembrolizumab for Participants With Muscle-Invasive Bladder Cancer Eligible for Cisplatin”.
Health-related quality of life with neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin ineligible: phase 3 KEYNOTE-905 study.
Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab in participants with cisplatin-ineligible muscle-invasive bladder cancer: an analysis of clinically relevant subgroups in KEYNOTE-905.
Enfortumab vedotin plus pembrolizumab vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma: 3.5-year follow-up and response analyses from the phase 3 EV-302 study.
Efficacy and safety of enzalutamide in patients with metastatic hormone-sensitive prostate cancer (mHSPC) and cardiometabolic comorbidities and/or related concomitant medications: ARCHES post hoc.
Predictors of treatment duration in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide: a post hoc analysis of ARCHES.
Outcomes with androgen-deprivation therapy plus androgen receptor pathway inhibitors in veterans with de novo metastatic castration-sensitive prostate cancer (mCSPC) who were elderly, frail, or had high comorbidity: a subgroup analysis of enzalutamide and high-volume disease.
HIGHLIGHT 1: A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for treatment of moderate to severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor-positive breast cancer who are receiving adjuvant endocrine therapy.
